HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock. Separately, Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a […]
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock. Separately, Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a […]
